Cencora

(New York Stock Exchange)
Back to all articles
Slightly Bullish +14

Seeking Clues to Cencora (COR) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

AI-generated analysis

πŸ“ˆ Wall Street analysts forecast Cencora (COR) quarterly earnings of $4.81 per share, representing an 8.8% year-over-year increase.

πŸ’° Expected revenues for the quarter are projected at $80.76 billion, marking a 7% increase from the previous year's quarter.

πŸ“‰ The consensus EPS estimate has been revised 0.3% lower over the last 30 days as analysts reevaluate their projections.

πŸ” Historical data indicates a strong correlation between earnings estimate revisions and short-term stock price performance.

πŸ’΅ Analysts predict 'Revenue- Total U.S. Healthcare Solutions' will reach $71.73 billion, up 5.1% year-over-year.

🌍 International healthcare revenue is estimated to hit $7.25 billion, showing a modest 1.1% year-over-year growth.

βš–οΈ Operating income for international solutions is forecast at $171.94 million compared to $159.30 million the prior year.

πŸ‡ΊπŸ‡Έ U.S. healthcare operating income is expected to reach $1.04 billion, slightly surpassing the previous year's reported $1.03 billion.

πŸ“‰ Cencora shares have declined 5.2% over the past month despite the Zacks S&P 500 composite rising by 10.5%.

πŸ“Š The stock currently holds a Zacks Rank #4 (Sell), suggesting it is expected to underperform the overall market in the near term.

Bullish Signals
  • Wall Street analysts project Cencora's quarterly earnings per share will increase by 8.8% year-over-year to $4.81.
  • Revenues are expected to reach $80.76 billion, representing a strong 7% growth compared to the previous quarter.
  • The U.S. Healthcare Solutions segment is forecast to generate $71.73 billion in revenue, up 5.1% year-over-year.
  • International Healthcare Solutions revenue is predicted to grow by 1.1% to $7.25 billion.
  • Operating income for International Healthcare Solutions is anticipated to rise to $171.94 million from $159.30 million last year.
  • U.S. Healthcare Solutions operating income is expected to reach $1.04 billion, demonstrating consistency against the prior year's $1.03 billion.
Risk Factors
  • Cencora shares have underperformed the broader market, dropping 5.2% in the past month compared to the S&P 500's 10.5% gain.
  • The stock carries a Zacks Rank #4 (Sell), indicating analysts expect CENCORA to significantly underperform the overall market in the near term.
  • Wall Street analysts have collectively revised their consensus EPS estimate downward by 0.3% over the last 30 days, suggesting a reassessment of growth expectations.
Full Analysis
Wall Street analysts anticipate that Cencora, Inc. (COR) will report quarterly earnings of $4.81 per share in its upcoming fiscal release, representing an 8.8% year-over-year increase. Revenue is projected to reach $80.76 billion, which would mark a 7% rise compared to the same quarter last year. Over the past 30 days prior to these earnings expectations, the consensus earnings per share estimate has been revised downward by 0.3%, reflecting analysts' recent reevaluation of the stock's fundamentals. Historical data indicates a strong correlation between earnings estimate revisions and short-term price movements, making this trend a significant factor for investors monitoring the company's potential market reaction. In terms of specific metric breakdowns, analysts forecast that revenue from Total U.S. Healthcare Solutions will total $71.73 billion, an increase of 5.1% year over year, while International Healthcare Solutions revenue is expected to hit $7.25 billion, a more modest 1.1% increase. Operating income for the international division is projected at $171.94 million, up from $159.30 million the prior year, whereas U.S. operating income estimates stand at $1.04 billion compared to $1.03 billion reported in the previous quarter's results. These granular projections provide insight into how different geographical segments may contribute to the overall financial performance ahead of the report release. Despite the positive revenue and earnings growth outlook, Cencora shares have declined 5.2% over the past month, contrasting sharply with the Zacks S&P 500 composite index's gain of 10.5%. Consequently, the stock currently holds a Zacks Rank #4, which is classified as a "Sell" rating, suggesting expectations that COR will underperform the broader market in the near term. This divergence between the fundamental earnings projections and recent stock price performance highlights the current bearish sentiment among analysts and investors despite the anticipated growth in key financial metrics for the quarter.